...Until Jerry Treppel was appointed CEO, the prospects for Elite had gradually improved with the achievement of significant milestones. We saw the quality of our leadership emerge after the FDA's Lodrane-24 recall threatened bankruptcy, and the implementation of strategic initiatives, which launched 7 drugs and one more in Naltrexone on the way to diversify its revenue streams, 2 ADT/ART patents, an FDA-DEA manufacturing facility, and financing by Lincoln Park Capital for $10 million. Elite appears to be thriving as it appears within the spotlight of the race for an FDA approval for its ADT/ART opioid pipeline. The days of treading water have long passed as stakeholders look forward to the company's financial performance from the upcoming quarterly report, and guidance from the conference call that is set to follow as it enters a new phase in its evolution. The writing is on the wall as many abusers of prescription pain medication gave an emphatic SOS(save our society) shout out to drug makers on the demand for ADT/ART opioids. Jerry Treppel's vision of creating a line of ADT/ART opioids should be seen with great optimism at best to better our society and improve the lives of individuals in dire need of pain medications to ease their suffering without the negative side-effects. Let's join Elite in realizing this dream for a better society come true. Cheers!
Market Data 
Markets 
AI
